ClinicalTrials.gg
RecruitingNCT05621070Updated Sep 19, 2024

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

A Phase 3 interventional study of JS002 and JS002 in Primary Hypercholesterolaemia and Mixed Dyslipidemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Dyslipidemias with a site in China — 23 open to participants now, 33 under way, 10 of them phase 3. Dyslipidemias · China.

Planned enrollment
14th of 58
582 · median 210
Started
2023
with 4 others
Phase 3
16 of 75
6 open now
Primary completion
2024-09
later than 4 of 32 live
Registered
43rd of 75
by date

Among the 75 studies in Dyslipidemias with a site in China, this one is the 14th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2023, is one of 16 in phase 3, reaches primary completion later than 4 of the 32 other live ones, and was the 43rd registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 75 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Dyslipidemias with a site in China, or all of them as a file.
02

Study summary

JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, PK/PD profile, immunogenicity as well as complete delivery of auto-injector by patients of JS002 as monotherapy in patients with primary hypercholesterolaemia and mixed dyslipidemia.

In this study, two dose cohorts(150 mg, 450 mg) are set up, and 582 subjects are planned to be enrolled (randomizedly assigned to JS002 or placebo 150/450 mg group in a 2:1:2:1 ratio).A screening period (≤6 weeks), a double-blind treatment period (12 weeks), an open-label treatment period (40 weeks), and a follow-up period (8 weeks) will be required.

03

Conditions studied

  • Primary Hypercholesterolaemia and Mixed Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Age 18\~80 years old
  3. Subject who has not achieve LDL-C goal as categorized by their CV risk at screening
  4. Fasting TG≤4.5mmol/L by central laboratory at screening
  5. Statin intolerance subject must have a history of statin intolerance as evidenced

Exclusion criteria

Exclusion Criteria:

  1. History of hemorrhagic stroke
  2. III or IV heart failure, or known \< 30% within 1 year before randomization
  3. Uncontrolled serious cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, within 90 days prior to randomization
  4. Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke, deep vein thrombosis or pulmonary embolism within 90 days prior to randomization
  5. Planned cardiac surgery or revascularization
  6. Uncontrolled hypertension defined as sitting systolic blood pressure(SBP) > 160 mmHg or diastolic BP (DBP) > 100 mmHg
  7. Type 1 diabetes, poorly controlled type 2 diabetes ( > 8%), newly diagnosed type 2 diabetes (within 90 days of randomization)
  8. Others factors not suitable for participation judged by PI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
582 participants (estimated)

Study arms

  • Experimental
    JS002 150mg Q2W

    JS002 150mg Q2W SC for 52 weeks

    Drug: JS002

  • Placebo comparator
    JS002 450mg Q4W

    JS002 450mg Q4W SC for 52 weeks

    Drug: JS002

  • Placebo comparator
    Placebo Q2W

    Placebo Q2W SC for 12 weeks, then switch to JS002 150mg Q2W SC for 40 weeks

    Drug: Placebo

  • Placebo comparator
    Placebo Q4W

    Placebo Q4W SC for 12 weeks, then switch to JS002 450mg Q4W SC for 40 weeks

    Drug: Placebo

Interventions

  • DrugOngericimabStudies of OngericimabOngericimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.

  • DrugOngericimabStudies of OngericimabOngericimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.

  • DrugPlacebo

    Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.

  • DrugPlacebo

    Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at Week 12

    Percent Change From Baseline in LDL-C at Week 12 in statin intolerance subjects

    Time frame: Baseline and week 12

  2. Percent Change From Baseline in LDL-C at Week 12

    Percent Change From Baseline in LDL-C at Week 12 in ITT subjects

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 12

    Change From Baseline in LDL-C at Week 12 in statin intolerance and ITT subjects

    Time frame: Baseline and week 12

  2. Percent Change From Baseline in LDL-C at Week 24,52

    Percent Change From Baseline in LDL-C at Week 24,52 in statin intolerance and ITT subjects

    Time frame: Baseline and week 24,52

  3. Change From Baseline in LDL-C at Week 24,52

    Change From Baseline in LDL-C at Week 24,52 in statin intolerance and ITT subjects

    Time frame: Baseline and week 24,52

  4. Percent Change From Baseline in other lipid parameters such as non-HDL-C, ApoB, TC, et al. at Week 12, 24, 52

    Percent Change From Baseline in other lipid parameters at Week 12, 24, 52 in statin intolerance and ITT subjects

    Time frame: Baseline and week 12, 24, 52

  5. Percentage of Participants With LDL-C Less Than 1.8 mmol/L(70 mg/dL)

    Percentage of Participants With LDL-C Less Than 1.8 mmol/L(70 mg/dL) at Week 12, 24, 52 in statin intolerance and ITT subjects

    Time frame: Baseline and week 12, 24, 52

  6. Percentage of Participants With Full Administration of JS002

    Percentage of Participants With Full Administration of JS002 at Weeks 12, 24, 52 in statin intolerance and ITT subjects

    Time frame: Baseline and week 12, 24, 52

Other outcomes

  1. Number of Participants with anti-drug antibodies (ADAs)

    Serum samples were analyzed for ADA. Positive samples were subsequently tested for neutralizing antibodies.

    Time frame: From baseline to week 60

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Sep 2024, 19 months after the start.

Of 62 phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 17, 2022
StartActual
Feb 3, 2023
Primary completionEst.
Sep 23, 2024
CompletionEst.
Sep 30, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05621070
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Feb 3, 2023
Primary completion
Sep 23, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Sep 19, 2024

Study contacts

Qiu'e Wan, PM
Contact
qiu.e_wan@junshipharma.com
86 17710342522

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion